Centogene NV (Centogene NV) ROCE % : 0.00% (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Centogene NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Centogene NV's annualized ROCE % for the quarter that ended in Jun. 2023 was 0.00%.

Centogene NV ROCE % Historical Data

The historical data trend for Centogene NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV ROCE % Chart

Centogene NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-24.78

-26.26

-67.72

-74.68

-56.81

Centogene NV Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-158.67	-61.72	-50.41	-	-

Centogene NV ROCE % Calculation

Centogene NV's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-37.103	/	( ( (102.979 - 44.539)	+	(98.318 - 26.128) )	/ 2 )
	=	-37.103	/	( (58.44	+	72.19)	/ 2 )
	=	-37.103	/	65.315
	=	-56.81 %

Centogene NV's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	0	/	( ( (98.318 - 26.128)	+	(77.889 - 29.146) )	/ 2 )
	=	0	/	( ( 72.19	+	48.743 )	/ 2 )
	=	0	/	60.4665
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Centogene NV (NAS:CNTG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Centogene NV ROCE % Related Terms

Thank you for viewing the detailed overview of Centogene NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Centogene NV (Centogene NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

39K:Germany

Address

Am Strande 7, Rostock, MV, DEU, 18055

Website

https://www.centogene.com

Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.